The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase II study (NCT05734495) of pirtobrutinib plus venetoclax in previously treated Waldenström’s macroglobulinemia (WM). Dr Castillo highlights that the study met its primary endpoint with 15 out of 27 patients achieving a very good partial response or complete response. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
